On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
For patients with commercial insurance
commercial patients with plaque psoriasis or psoriatic arthritis have preferred access to Otezla with
no biologic step required1
DMARD, disease-modifying antirheumatic drug.
Reference: 1. Data on file, Amgen Inc.
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Warnings and Precautions
Use in Specific Populations